The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. METHODS: We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more. RESULTS: Among the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. CONCLUSIONS: Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inter- and intra-driver heterogeneity are also evident following treatment with inhibitors of the immune checkpoint molecules PD-1 or PD-L1, with only ~20% of unselected NSCLC patients deriving durable clinical benefit38–43.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [39]
In the citing paper
“other features such as TMB appear to also be associated with clinical benefit to PD-1 / PD-L1 antibodies”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I. O., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 758
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,001
Keeping Expectations in Check With Immune Checkpoint Inhibitors
Temel, J. S., Gainor, J. F., Sullivan, R. J., & Greer, J. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2146 · Cited by 62
Rossi, G., Russo, A., Tagliamento, M., Tuzi, A., Nigro, O., Vallome, G., Sini, C., Grassi, M., Bello, M. G. D., Coco, S., et al. (2020) · Cancers · doi:10.3390/cancers12051125 · Cited by 61
Kim, J., Hong, J., Lee, J., Lahiji, S. F., & Kim, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.002 · Cited by 62
Patient performance status and cancer immunotherapy efficacy: a meta-analysis
Bersanelli, M., Brighenti, M., Buti, S., Barni, S., & Petrelli, F. (2018) · Medical Oncology · doi:10.1007/s12032-018-1194-4 · Cited by 64
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
Jafarnejad, M., Gong, C., Gabrielson, E., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L. K., & Popel, A. S. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0350-x · Cited by 60
Ascierto, P. A., Bifulco, C. B., Palmieri, G., Peters, S., & Sidiropoulos, N. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.05.004 · Cited by 65
Self-citationAdvances in Small-Cell Lung Cancer (SCLC) Translational ResearchPreprint
Drapkin, B. J., & Rudin, C. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038240 · Cited by 63
A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC
Pan, D., Hu, A. Y., Antonia, S. J., & Li, C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.021 · Cited by 60
Vaddepally, R. K., Doddamani, R., Sodavarapu, S., Madam, N. R., Katkar, R. B., Kutadi, A. P., Mathew, N., Garje, R., & Chandra, A. B. (2022) · Biomedicines · doi:10.3390/biomedicines10040790 · Cited by 64
Hou, J., Li, H., Ma, S., He, Z., Yang, S., Hao, L., Zhou, H., Zhang, Z., Han, J., Wang, L., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00372-6 · Cited by 62
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 60
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
Santaniello, A., Napolitano, F., Servetto, A., Placido, P. D., Silvestris, N., Bianco, C., Formisano, L., & Bianco, R. (2019) · Cancers · doi:10.3390/cancers11101419 · Cited by 61
Brown, H. J., Vansteenkiste, J., Nakagawa, K., Cobo, M., John, T., Barker, C., Kohlmann, A., Todd, A., Saggese, M., Chmielecki, J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.009 · Cited by 61
New developments in systemic therapy for advanced biliary tract cancer
Morizane, C., Ueno, M., Ikeda, M., Okusaka, T., Ishii, H., & Furuse, J. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy082 · Cited by 61
Update on liquid biopsy in clinical management of non-small cell lung cancer
Wu, Z., Yang, Z., Dai, Y., Zhu, Q., & Chen, L.-A. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s203070 · Cited by 63
Gao, P., Wang, Z., Hu, Z., Jiao, X., & Yao, Y. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29484 · Cited by 60
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 62
The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer
Haruna, M., Ueyama, A., Yamamoto, Y., Hirata, M., Goto, K., Yoshida, H., Higuchi, N., Yoshida, T., Kidani, Y., Nakamura, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09458-5 · Cited by 56
Pacheco, J. M., Camidge, D. R., Doebele, R. C., & Schenk, E. L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00195 · Cited by 60
She, L., Hu, H., Liao, M., Xia, X., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Shen, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.017 · Cited by 60
Self-citationFormate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
Rowe, J. H., Elia, I., Shahid, O., Gaudiano, E. F., Sifnugel, N. E., Johnson, S., Reynolds, A. G., Fung, M. E., Joshi, S., LaFleur, M. W., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1301 · Cited by 59
Tian, Y., Zhai, X., Yan, W., Zhu, H., & Yu, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3590 · Cited by 58
Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer
Zhang, P., Dai, J., Sun, F., Xia, H., He, W., Duan, L., Liu, M., Zhao, D., Zhu, Y., & Jiang, G. (2022) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2022.01.039 · Cited by 59
Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 57
Akbar, S., Raza, A., Mohsin, R., Kanbour, A., Qadri, S. M., Parray, A., Gul, A. R. Z., Philip, A., Vijayakumar, S., Merhi, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1097117 · Cited by 63
TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer
Looney, T. J., Topacio-Hall, D., Lowman, G., Conroy, J. M., Morrison, C., Oh, D. Y., Fong, L. H., & Zhang, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02985 · Cited by 58
Krieger, T., Pearson, I. V., Bell, J. A., Doherty, J. P., & Robbins, P. B. (2020) · Diagnostic Pathology · doi:10.1186/s13000-020-0927-9 · Cited by 61
Chen, Y., Wang, Y., Luo, H., Meng, X., Zhu, W., Wang, D., Zeng, H., & Zhang, H. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00173-3 · Cited by 58
SMARCA4 mutations in KRAS ‐mutant lung adenocarcinoma: a multi‐cohort analysis
Liu, L., Ahmed, T., Petty, W. J., Grant, S. C., Ruiz, J., Lycan, T. W., Topaloĝlu, Ü., Chou, P., Miller, L. D., Hawkins, G. A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12831 · Cited by 58
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
Isaacs, J. M., Anders, C. K., McArthur, H. L., & Force, J. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00833-4 · Cited by 60
Cancer neoantigens as potential targets for immunotherapy
Ma, W., Pham, B., & Li, T. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10091-1 · Cited by 63
Zhou, J., Chao, Y., Yao, D., Ding, N., Li, J., Gao, L., Zhang, Y., Xu, X., Zhou, J., Halmos, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-214 · Cited by 58
Immune Checkpoint Inhibitors in the Management of Lung Cancer
Zimmermann, S., Peters, S., Owinokoko, T., & Gadgeel, S. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201319 · Cited by 59
Self-citationFrederickson, A. M., Arndorfer, S., Zhang, I., Lorenzi, M. F., Insinga, R. P., Arunachalam, A., Burke, T. A., & Simon, G. R. (2019) · Immunotherapy · doi:10.2217/imt-2018-0193 · Cited by 58
First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
Bylicki, O., Barazzutti, H., Paleiron, N., Margery, J., Assié, J., & CHOUAID, C. (2019) · BioDrugs · doi:10.1007/s40259-019-00339-4 · Cited by 60
Low, J. L., Walsh, R. J., Ang, Y. L. E., Chan, G. H. J., & Soo, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919870360 · Cited by 59
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00090 · Cited by 58
Immunotherapy in surgically resectable non-small cell lung cancer
Owen, D. H., & Chaft, J. E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.93 · Cited by 57
Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events
Farooq, M. Z., Aqeel, S. B., Lingamaneni, P., Pichardo, R., Jawed, A., Khalid, S., Banskota, S. U., Fu, P., & Mangla, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7722 · Cited by 63
FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC
Chi, H., Gao, X., Xia, Z., Yu, W., Yin, X., Pan, Y., Peng, G., Mao, X., Teichmann, A. T., Zhang, J., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1200335 · Cited by 57
Lin, S., Yang, C., Liao, B.-C., Ho, C., Liao, W., Chen, K., Tsai, T.-H., Hsu, C., Hsu, W., Su, K., et al. (2018) · Journal of Cancer · doi:10.7150/jca.24985 · Cited by 57
Nie, R., Chen, F., Yuan, S., Luo, Y.-S., Chen, S., Chen, Y., Chen, X., Chen, Y.-B., Li, Y., & Zhou, Z. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.011 · Cited by 59
Wang, C., Qiao, W., Jiang, Y., Zhu, M., Shao, J., Ren, P., Liu, D., & Li, W. (2019) · Cancer Medicine · doi:10.1002/cam4.2280 · Cited by 59
Wagner, G., Stollenwerk, H. K., Klerings, I., Pecherstorfer, M., Gartlehner, G., & Singer, J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774314 · Cited by 60
Wiesweg, M., Mairinger, F. D., Reis, H., Goetz, M., Kollmeier, J., Misch, D., Stephan-Falkenau, S., Mairinger, T., Walter, R. F. H., Hager, T., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.015 · Cited by 56
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54
He, K., Barsoumian, H. B., Puebla‐Osorio, N., Hu, Y. Y., Sezen, D., Wasley, M. D., Bertolet, G., Zhang, J., Leuschner, C., Yang, L., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0547 · Cited by 58
Chen, Y., Wang, Z., Jin, Y., Zhao, Q., Liu, Z., Zuo, Z., Ju, H., Cui, C., Yao, J., Zhang, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.016 · Cited by 58
Wei, F., Azuma, K., Nakahara, Y., Saito, H., Matsuo, N., Tagami, T., Kouro, T., Igarashi, Y., Tokito, T., Kato, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006788 · Cited by 58
Affolter, T., Llewellyn, H. P., Bartlett, D. W., Zong, Q., Xia, S., Torti, V. R., & Ji, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217276 · Cited by 58
Kroeze, L. I., de Voer, R. M., Kamping, E. J., von Rhein, D. T., Jansen, E. A. M., Hermsen, M. J. W., Barberis, M. C. P., Botling, J., Garrido-Martin, E. M., Haller, F., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.02.009 · Cited by 57
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Sundar, R., Smyth, E. C., Peng, S., Yeong, J. P.-S., & Tan, P. B. O. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00763 · Cited by 55
Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore
Li, R., Han, D., Shi, J., Han, Y., Tan, P., Zhang, R., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188420 · Cited by 57
Bravaccini, S., Bronte, G., & Ulivi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126536 · Cited by 60
Ling, Y., Li, N., Li, L., Guo, C., Wei, J., Yuan, P., Tan, F., Tao, X., Wang, S., Wang, Z., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00135-2 · Cited by 57
Maghrouni, A., Givari, M., Jalili‐Nik, M., Mollazadeh, H., Bibak, B., Sadeghi, M. M., Afshari, A. R., Johnston, T. P., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107403 · Cited by 56
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Rahman, M. M., Behl, T., Islam, M. R., Islam, M. R., Islam, M. R., Albarrati, A., Albratty, M., Meraya, A. M., & BUNGAU, S. G. (2022) · Molecules · doi:10.3390/molecules27123798 · Cited by 55
Hou, X., Zhou, C., Wu, G., Lin, W., Xie, Z., Zhang, H., Yi, J., Peng, Z., Yin, L., Ma, C., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.083 · Cited by 55
Federico, A. D., Alden, S. L., Smithy, J. W., Ricciuti, B., Alessi, J. V., Wang, X., Pecci, F., Lamberti, G., Gandhi, M. M., Vaz, V. R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.014 · Cited by 57
Nagai, H., & Muto, M. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1259-6 · Cited by 55
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 57
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Zhou, X., Qu, M., Tebon, P. J., Jiang, X., Wang, C., Xue, Y., Zhu, J., Zhang, S., Öklü, R., Sengupta, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001447 · Cited by 55
Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma
Mantia, C. M., & McDermott, D. F. (2019) · Cancer · doi:10.1002/cncr.32361 · Cited by 55
Cottrell, T. R., Lotze, M. T., Ali, A. M., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 65
Nivolumab Plus Ipilimumab in Non-Small-Cell Lung Cancer
Reck, M., Borghaei, H., & O'Byrne, K. J. (2019) · Future Oncology · doi:10.2217/fon-2019-0031 · Cited by 56
Self-citationHan, C., Sasson, A., Srinivasan, S., Golhar, R., Greenawalt, D. M., Geese, W. J., Green, G. A., Zerba, K. E., Kirov, S. A., & Szustakowski, J. D. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00408-y · Cited by 56
Self-citationPrognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients
Sridhar, S., Paz-Ares, L. G., Liu, H., Shen, K., Morehouse, C., Rizvi, N. A., Segal, N. H., Jin, X., Zheng, Y., Narwal, R., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.020 · Cited by 53
Self-citationBeyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy
Lagos, G., Izar, B., & Rizvi, N. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_289967 · Cited by 54
Rashid, R., Gaglia, G., Chen, Y.-A., Lin, J., Du, Z., Maliga, Z., Schapiro, D., Yapp, C., Muhlich, J. L., Sokolov, A., et al. (2019) · Scientific Data · doi:10.1038/s41597-019-0332-y · Cited by 50
Pu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 56
Yao, J., Gong, Y., Zhao, W., Han, Z., Guo, S., Liu, H., Peng, X., Xiao, W., Li, Y., Dang, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52414-z · Cited by 53
Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
Niu, Y., Lin, A., Luo, P., Zhu, W., Wei, T., Tang, R., Guo, L., & Zhang, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01213 · Cited by 54
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade
Miyai, Y., Sugiyama, D., Hase, T., Asai, N., Taki, T., Nishida, K., Fukui, T., Chen-Yoshikawa, T. F., Kobayashi, H., Mii, S., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101230 · Cited by 55
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54
Stein, M. K., Pandey, M. K., Xiu, J., Tae, H., Swensen, J. J., Mittal, S., Brenner, A. J., Korn, W. M., Heimberger, A. B., & Martin, M. G. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00376 · Cited by 54
Wang, M., Liang, H., Wang, W., Zhao, S., Cai, X., Zhao, Y., Li, C., Cheng, B., Xiong, S., Li, J., et al. (2020) · Cancer · doi:10.1002/cncr.33270 · Cited by 53
Fu, J., Li, W., McGrath, N., Lai, C. W., Brar, G., Xiang, Y., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 53
Vryza, P., Fischer, T., Mistakidi, E., & Zaravinos, A. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101788 · Cited by 55
de Alencar, V. T. L., Camandaroba, M. P. G., Pirolli, R., Fogassa, C. A. Z., & de Lima, V. C. C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.014 · Cited by 53
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
Melosky, B. L., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Ionescu, D. N., Tsao, M., McLeod, D., & Hirsh, V. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.005 · Cited by 51
Self-citationImmunosenescence, inflammaging, and cancer immunotherapy efficacy
Rodriguez, J. E., Naigeon, M., Goldschmidt, V., Dugage, M. R., Seknazi, L., Danlos, F., Champiat, S., Marabelle, A., Michot, J., Massard, C., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2098718 · Cited by 55
Combining stereotactic body radiation therapy with immunotherapy: current data and future directions
Lin, A. J., Roach, M. C., Bradley, J. D., & Robinson, C. G. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.16 · Cited by 49
Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology
Bartha, Á., & Győrffy, B. (2019) · Cancers · doi:10.3390/cancers11111725 · Cited by 58
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
Knudson, K. M., Hicks, K. C., Ozawa, Y., Schlom, J., & Gameiro, S. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000493 · Cited by 50
Cui, P., Li, R., Huang, Z., Wu, Z., Tao, H., Zhang, S., & Hu, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-70207-7 · Cited by 51
Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer
Fan, Z., Zhang, Q., Li, F., Wang, L., Zhou, X., Han, J., Li, D., Liu, J., Zhang, X., Zuo, J., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-412 · Cited by 50
PD-L1 as a biomarker in NSCLC: challenges and future directions
Mathew, M., Safyan, R. A., & Shu, C. A. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.04 · Cited by 50
Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer
Zhang, J., Wolfgang, C. L., & Zheng, L. (2018) · Cancers · doi:10.3390/cancers10020039 · Cited by 52
Sakai, H., Takeda, M., Sakai, K., Nakamura, Y., Ito, A., Hayashi, H., Tanaka, K., Nishio, K., & Nakagawa, K. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.025 · Cited by 53
Cho, Y., Choi, M. G., Kim, D. H., Choi, Y. J., Kim, S. Y., Sung, K. J., Lee, J. C., Kim, S., Rho, J. K., & Choi, C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00712-2 · Cited by 50
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
Banna, G. L., Cantale, O., Bersanelli, M., Re, M. D., Friedlaender, A., Cortellini, A., & Addeo, A. (2020) · Oncology Reviews · doi:10.4081/oncol.2020.490 · Cited by 50
Dall’Olio, F. G., Abbati, F., Facchinetti, F., Massucci, M., Melotti, B., Squadrilli, A., Buti, S., Formica, F., Tiseo, M., & Ardizzoni, A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920952994 · Cited by 51
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
Sagawa, R., Sakata, S., Gong, B., Seto, Y., Takemoto, A., Takagi, S., Ninomiya, H., Yanagitani, N., Nakao, M., Mun, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.153323 · Cited by 50
Rajakumar, T., Horos, R., Jehn, J., Schenz, J., Muley, T., Pelea, O., Hofmann, S., Kittner, P., Kahraman, M., Heuvelman, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00262-y · Cited by 52
Self-citationLin, Z., Zou, J., Sui, X., Yao, S., Lin, L., Wang, J., & Zhao, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-20858-5 · Cited by 49
Progress in the Management of Advanced Thoracic Malignancies in 2017
Ferrara, R., Mezquita, L., & Besse, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.002 · Cited by 50
Faiena, I., Cummings, A. L., Crosetti, A. M., Pantuck, A. J., Chamie, K., & Drakaki, A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s141491 · Cited by 49
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 49
Novel Biomarkers for Personalized Cancer Immunotherapy
Shindo, Y., Hazama, S., Tsunedomi, R., Suzuki, N., & Nagano, H. (2019) · Cancers · doi:10.3390/cancers11091223 · Cited by 49
Metadata
- Authors
- Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., Ready, N., Hiltermann, T. J. N., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J. M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein, G. R., Villaruz, L. C., Havel, L., Krejci, J., Corral Jaime, J., Chang, H., Geese, W. J., Bhagavatheeswaran, P., Chen, A. C., & Socinski, M. A.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Carbone, David P.
- Reck, Martin
- Paz-Ares, Luis
- Horn, Leora
- Felip, Enriqueta
- Ciuleanu, Tudor-Eliade
- Badin, Firas
- Ready, Neal
- Hiltermann, T. Jeroen N.
- Nair, Suresh
- Juergens, Rosalyn
- Peters, Solange
- Wrangle, John M.
- Borghaei, Hossein
- Blumenschein, George R.
- Villaruz, Liza C.
- Havel, Libor
- Chang, Han
- Geese, William J.
- Socinski, Mark A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-06-22
- Volume
- 376
- Issue
- 25
- Pages
- 2415-2426
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6487310
- OpenAlex
- W2635951006
- Cited by
- 2,503
- References
- 20
- Citations by year
- 2026: 54 · 2025: 121 · 2024: 196 · 2023: 223 · 2022: 328 · 2021: 380 · 2020: 432 · 2019: 372 · 2018: 334 · 2017: 61
- FWCI
- 144.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- IRIS (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lirias (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (UG1CA233259, K12CA157688, P30CA016672, P30CA016058)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, non-small cell lung cancer, PD-L1 expression, first-line therapy, stage IV NSCLC, recurrent NSCLC, platinum-based chemotherapy, docetaxel, progression-free survival, overall survival, immune checkpoint inhibitors, treatment-related adverse events, PD-1 inhibitors, PD-L1 inhibitors, PD-1/PD-L1 blockade
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Disease-Free Survival, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
